OBJECTIVE: Describe characteristics, daily care and outcomes of patients with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). DESIGN: Case series of 73 patients. SETTING: Large tertiary hospital in Milan. PARTICIPANTS: Mechanically ventilated patients with confirmed COVID-19 admitted to the intensive care unit (ICU) between 20 February and 2 April 2020. MAIN OUTCOME MEASURES: Demographic and daily clinical data were collected to identify predictors of early mortality. RESULTS: Of the 73 patients included in the study, most were male (83.6%), the median age was 61 years (interquartile range [IQR], 54-69 years), and hypertension affected 52.9% of patients. Lymphocytopenia (median, 0.77 x 103 per mm3; IQR, 0.58-1.00 x 103 per mm3), hyperinflammation with C-reactive protein (median, 184.5 mg/dL; IQR, 108.2-269.1 mg/dL) and pro-coagulant status with D-dimer (median, 10.1 μg/m; IQR, 5.0-23.8 μg/m) were present. Median tidal volume was 6.7 mL/kg (IQR, 6.0-7.5 mL/kg), and median positive end-expiratory pressure was 12 cmH2O (IQR, 10-14 cmH2O). In the first 3 days, prone positioning (12-16 h) was used in 63.8% of patients and extracorporeal membrane oxygenation in five patients (6.8%). After a median follow-up of 19.0 days (IQR, 15.0-27.0 days), 17 patients (23.3%) had died, 23 (31.5%) had been discharged from the ICU, and 33 (45.2%) were receiving invasive mechanical ventilation in the ICU. Older age (odds ratio [OR], 1.12; 95% CI, 1.04-1.22; P = 0.004) and hypertension (OR, 6.15; 95% CI, 1.75-29.11; P = 0.009) were associated with mortality, while early improvement in arterial partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) ratio was associated with being discharged alive from the ICU (P = 0.002 for interaction). CONCLUSIONS: Despite multiple advanced critical care interventions, COVID-19 ARDS was associated with prolonged ventilation and high short term mortality. Older age and pre-admission hypertension were key mortality risk factors. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04318366.
OBJECTIVE: Describe characteristics, daily care and outcomes of patients with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). DESIGN: Case series of 73 patients. SETTING: Large tertiary hospital in Milan. PARTICIPANTS: Mechanically ventilated patients with confirmed COVID-19 admitted to the intensive care unit (ICU) between 20 February and 2 April 2020. MAIN OUTCOME MEASURES: Demographic and daily clinical data were collected to identify predictors of early mortality. RESULTS: Of the 73 patients included in the study, most were male (83.6%), the median age was 61 years (interquartile range [IQR], 54-69 years), and hypertension affected 52.9% of patients. Lymphocytopenia (median, 0.77 x 103 per mm3; IQR, 0.58-1.00 x 103 per mm3), hyperinflammation with C-reactive protein (median, 184.5 mg/dL; IQR, 108.2-269.1 mg/dL) and pro-coagulant status with D-dimer (median, 10.1 μg/m; IQR, 5.0-23.8 μg/m) were present. Median tidal volume was 6.7 mL/kg (IQR, 6.0-7.5 mL/kg), and median positive end-expiratory pressure was 12 cmH2O (IQR, 10-14 cmH2O). In the first 3 days, prone positioning (12-16 h) was used in 63.8% of patients and extracorporeal membrane oxygenation in five patients (6.8%). After a median follow-up of 19.0 days (IQR, 15.0-27.0 days), 17 patients (23.3%) had died, 23 (31.5%) had been discharged from the ICU, and 33 (45.2%) were receiving invasive mechanical ventilation in the ICU. Older age (odds ratio [OR], 1.12; 95% CI, 1.04-1.22; P = 0.004) and hypertension (OR, 6.15; 95% CI, 1.75-29.11; P = 0.009) were associated with mortality, while early improvement in arterial partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) ratio was associated with being discharged alive from the ICU (P = 0.002 for interaction). CONCLUSIONS: Despite multiple advanced critical care interventions, COVID-19ARDS was associated with prolonged ventilation and high short term mortality. Older age and pre-admission hypertension were key mortality risk factors. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04318366.
Authors: Tereza Prokopová; Jan Hudec; Kamil Vrbica; Jan Stašek; Andrea Pokorná; Petr Štourač; Kateřina Rusinová; Paulína Kerpnerová; Radka Štěpánová; Adam Svobodník; Jan Maláska Journal: Crit Care Date: 2022-07-19 Impact factor: 19.334
Authors: Adam S Faye; Kate E Lee; Monika Laszkowska; Judith Kim; John William Blackett; Anna S McKenney; Anna Krigel; Jon T Giles; Runsheng Wang; Elana J Bernstein; Peter H R Green; Suneeta Krishnareddy; Chin Hur; Benjamin Lebwohl Journal: J Rheumatol Date: 2020-11-01 Impact factor: 4.666
Authors: Sarah W Robison; JinDong Li; Liliana Viera; Jonathan P Blackburn; Rakesh P Patel; J Edwin Blalock; Amit Gaggar; Xin Xu Journal: JCI Insight Date: 2021-04-08
Authors: Christine J Kubin; Thomas H McConville; Donald Dietz; Jason Zucker; Michael May; Brian Nelson; Elizabeth Istorico; Logan Bartram; Jennifer Small-Saunders; Magdalena E Sobieszczyk; Angela Gomez-Simmonds; Anne-Catrin Uhlemann Journal: Open Forum Infect Dis Date: 2021-05-05 Impact factor: 3.835
Authors: Simone Gulletta; Paolo Della Bella; Luigi Pannone; Giulio Falasconi; Lorenzo Cianfanelli; Savino Altizio; Elena Cinel; Valentina Da Prat; Antonio Napolano; Giuseppe D'Angelo; Luigia Brugliera; Eustachio Agricola; Giovanni Landoni; Moreno Tresoldi; Patrizia Querini Rovere; Fabio Ciceri; Alberto Zangrillo; Pasquale Vergara Journal: J Interv Card Electrophysiol Date: 2021-07-22 Impact factor: 1.759
Authors: Jan Matthias Kruse; Daniel Zickler; Willie M Lüdemann; Sophie K Piper; Inka Gotthardt; Jana Ihlow; Selina Greuel; David Horst; Andreas Kahl; Kai-Uwe Eckardt; Sefer Elezkurtaj Journal: Sci Rep Date: 2021-08-06 Impact factor: 4.379